INTRODUCTION
============

Inflammation involves a tightly regulated process, characterized by two complementary subsystems: the innate immune system and the subsequent, highly adaptive immune system. The innate immune system is activated by invasive pathogens that target pattern recognition receptors (PRRs), such as membrane-bound Toll-like receptors (TLRs) and cytosolic NOD-like receptors (NLRs). While TLRs detect both extracellular and intracellular stimuli, NLRs respond to cytosolic agonists. The NLR family contains various proteins that act as scaffolds that can oligomerize into larger protein complexes, thereby inducing the formation of a molecular platform called the inflammasome. These multi-protein complexes contribute to the activation of inflammatory caspases (i.e., caspase-1) that result in the proteolytic processing and secretion of cytokines, including interleukin (IL)-1β and IL-18 ([@b49-molcell-37-6-441]). Therefore, inflammasomes, which include members of the NLR family (i.e., NLRP1, NLRP3, and IPAF) as well as the PYHIN family member AIM2, represent critical mediators of cellular stress in the innate and adaptive immune systems ([Fig. 1](#f1-molcell-37-6-441){ref-type="fig"}). This review will discuss the importance of inflammasome pathways, specifically, that of the most fully characterized NLRP3 inflammasome, in metabolic and cognitive diseases, including obesity, type 2 diabetes mellitus, Alzheimer's disease, and major depressive disorder ([Fig. 2](#f2-molcell-37-6-441){ref-type="fig"}).

STRUCTURAL ORGANIZATION
=======================

The NLR family
--------------

The NLR protein family consists of the NLRPs (NLRP1-14, or NALP1-14) and the ICE-protease-activating factor (IPAF) sub-family. Most NLRs contain the nucleotide-binding and oligomerization (NACHT) domain, which enables activation of the pro-inflammatory cytokine signaling pathways *via* ATP-dependent oligomerization. The NACHT domain is usually surrounded by C-terminal leucine-rich repeats (LRRs) and an N-terminal caspase and recruitment domain (CARD) or pyrin domain (PYD) ([@b66-molcell-37-6-441]). The PYD domain of NLRPs recruits the adaptor apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), which contains an N-terminal PYD and a C-terminal CARD. Furthermore, the CARD domain of ASC represents an essential component for inflammasome formation *via* caspase-1 binding ([@b46-molcell-37-6-441]; [@b47-molcell-37-6-441]).

The NLRP1, NLRP3, and IPAF inflammasomes harbor structural distinctions that enable caspase-1 recruiting. The NLRP1 inflammasome contains a C-terminal CARD that recruits procaspase-1 ([@b13-molcell-37-6-441]) or pro-caspase-5 ([@b47-molcell-37-6-441]). As a result, NLRP1 does not require recruitment of ASC to interact directly with caspase-1. However, ASC has been shown to enhance NLRP1-mediated caspase-1 activation *in vitro* ([@b13-molcell-37-6-441]). In contrast to most proteins of the NLR family, the NLRP3 protein lacks the typical CARD domain. The PYD domain of NLRP3 interacts with ASC, whose CARD domain recruits the CARD of pro-caspase-1 ([@b66-molcell-37-6-441]). Finally, the IPAF protein lacks a PYD domain ([@b66-molcell-37-6-441]), but contains a CARD domain that interacts directly with pro-caspase-1 without the need of ASC ([@b60-molcell-37-6-441]). Therefore, IPAF may interact with a PYD-containing protein (i.e., NLRPs) for appropriate inflammatory responses to invasive pathogens ([@b66-molcell-37-6-441]).

AIM2 inflammasome
-----------------

The pyrin and HIN domain-containing protein (PYHIN) family member absent in melanoma 2 (AIM2 inflammasome) represents the first non-NLR family member identified that can form an inflammasome complex ([@b43-molcell-37-6-441]; [@b66-molcell-37-6-441]). While most inflammasomes in the NLR family depend on a central NACHT domain for oligomerization, AIM2 uses multiple binding sites for cytosolic DNA *via* its C-terminal HIN200 domain. Similar to NLRP3, AIM2 contains a PYD domain that interacts with ASC *via* homotypic PYD-PYD interactions, which allows the CARD domain within ASC to regulate nuclear factor kappa B (NF-κB) and caspase-1 production ([@b28-molcell-37-6-441]). As a result, AIM2-mediated caspase-1 activation induces pro-inflammatory cytokine secretion (i.e., IL-1β, IL-18) ([@b66-molcell-37-6-441]).

NLRP3 INFLAMMASOME ACTIVATION AND REGULATION
============================================

TLR-dependence
--------------

TLRs are critical receptors that regulate inflammasome activity and pro-IL-1β production. TLR agonists, such as lipopolysaccharide (LPS), induce pro-IL-1β secretion *via* the NF-κB transcription factor and IL-1β promoter activation ([@b25-molcell-37-6-441]; [@b66-molcell-37-6-441]). Prior to caspase-1-mediated proteolytic cleavage of IL-1β, TLR agonists facilitate the NLRP3 inflammasome pathway through an NF-κB-dependent priming signal, which may represent a rate-limiting component of inflammasome complex formation ([@b4-molcell-37-6-441]; [@b20-molcell-37-6-441]). Other studies have suggested the importance of TLR4 in the inflammasome pathway. For example, CD14, a phagocyte-expressed PRR known to interact with TLR4, increased TLR4-mediated inflammatory response to LPS ([@b17-molcell-37-6-441]) and monosodium urate (MSU) ([@b68-molcell-37-6-441]). Furthermore, LPS failed to induce NLRP3 or pro-IL-1β activation in cells lacking a functional TLR4 receptor ([@b4-molcell-37-6-441]). [@b16-molcell-37-6-441] demonstrated that the presence of ATP was required for TLR4-dependent caspase-1 activation following exposure to LPS.

ATP-dependence
--------------

Extracellular ATP activates the P2X purinoreceptor 7 (P2X~7~R) *via* the pannexin-1 hemichannel, which was proposed to permit the bacterial ligand to enter the cytosol to induce caspase-1 expression ([@b33-molcell-37-6-441]). P2X~7~R-dependent procaspase-1 activation and IL-1β secretion have been found to facilitate NF-κB activation *via* a TNF-α-dependent pathway, thereby suggesting an important role of P2X~7~R in NLRP3 inflammasome complex formation ([@b71-molcell-37-6-441]; [@b82-molcell-37-6-441]). ATP-mediated P2X~7~R stimulation has also been shown to induce a K^+^ efflux, which indicates that reduced intracellular K^+^ concentration triggers the NLRP3 inflammasome pathway ([@b59-molcell-37-6-441]). Furthermore, suppressed NLRP3 activity has been reported to result from treatment with the ATP-sensitive K^+^ channel inhibitor, glibenclamide, and the chemical ROS scavenger, (2R,4R)-4-aminopyrrolidine-2, 4-dicarboxylate (APDC) ([@b2-molcell-37-6-441]; [@b55-molcell-37-6-441]). However, P2X~7~R-deficient and wild type mice exhibit similar levels of adipocyte cell death in a diet-induced obesity model ([@b74-molcell-37-6-441]). Furthermore, a recent study has shown that pannexin-1 is not required for P2X~7~R function during activation of the NLRP3, IPAF, and AIM2 inflammasomes ([@b62-molcell-37-6-441]). As a result, activation of the inflammasome pathway may not strictly depend on the presence of ATP *in vivo*.

Alternative pathways and ROS-dependence
---------------------------------------

Recent studies have proposed an alternative model for NLRP3 inflammasome formation that involves lysosomal destabilization due to engulfment of crystalline or particulate agonists ([@b66-molcell-37-6-441]). For example, macrophage cells treated with silica crystals or MSU displayed swollen lysosomes and dispersion of lysosomal contents in the cytosol ([@b27-molcell-37-6-441]). The antibiotic nigericin can induce lysosomal rupture *via* cathepsin B, a cysteine protease found in the lysosome, and subsequent caspase-1 activation *via* K^+^ efflux ([@b22-molcell-37-6-441]; [@b24-molcell-37-6-441]). Moreover, since pannexin-1 is required for nigericin-induced NLRP3 inflammasome formation ([@b57-molcell-37-6-441]; [@b58-molcell-37-6-441]) and enables larger lysosomal pores, pannexin-1 may induce lysosomal destabilization ([@b27-molcell-37-6-441]). Furthermore, the same study reported that cells undergoing lysosomal rupture lose cathepsin B, thereby inducing caspase-1 activation, which suggests that the NLRP3 inflammasome recognizes lysosomal damage and subsequent lysosomal content in the cytoplasm following phagocytosis of NLRP3 agonists ([@b27-molcell-37-6-441]).

Environmental stimuli, such as asbestos and silica, can activate the NLRP3 inflammasome complex *via* phagocytic NADPH oxidase-induced reactive oxygen species (ROS) production ([@b9-molcell-37-6-441]). For example, NADPH oxidase inhibitors, diphenylene iodonium (DPI) and apocynin, and knockdown of the NADPH oxidase subunit p22^phox^ have been shown to reduce IL-1β production. Similar inhibitory effects on inflammasome activation have been reported for ROS inhibitors, N-acetyl-L-cysteine (NAC) and APDC, in response to asbestos, MSU, and ATP ([@b9-molcell-37-6-441]). P2X~7~R has been shown to mediate NADPH oxidase-dependent oxidative stress both *in vivo* ([@b5-molcell-37-6-441]) and *in vitro* ([@b36-molcell-37-6-441]; [@b41-molcell-37-6-441]), thereby indicating a critical role for P2X~7~R in activation of the NLRP3 inflammasome *via* ROS signaling.

Furthermore, recent studies suggest that treatment of macrophages with the mitochondria-targeted antioxidant Mito-TEMPO, a TEMPOL derivative that targets mitochondrial ROS ([@b75-molcell-37-6-441]), reduced secretion of both IL-1β and IL-18. Mito-TEMPO inhibited subsequent caspase-1 activation and mitochondrial DNA (mtDNA) translocation to the cytosol in response to LPS and ATP ([@b55-molcell-37-6-441]). However, Mito-TEMPO did not inhibit IL-1β secretion following exposure to treatment with LPS and MSU, indicating that this pathway is independent of mitochondrial ROS ([@b55-molcell-37-6-441]). In conclusion, while ROS production represents a critical prerequisite to the NLRP3 inflammasome pathway, the source of ROS may vary with experimental models.

NLRP3 inflammasome in metabolic disorders
-----------------------------------------

Recently, the prevalence of metabolic disorders, such as obesity, type 2 diabetes mellitus (T2DM), and atherosclerosis has risen tremendously ([@b6-molcell-37-6-441]). The World Health Organization (WHO) estimates that over 2.8 million adults above the age of 20 die each year worldwide due to being overweight (BMI ≥ 25 kg/m^2^) or suffering from obesity (BMI ≥ 30 kg/m^2^). In 2008, 10--14% of adults were clinically obese, in contrast to 5--8% of men and women in 1980 ([@b15-molcell-37-6-441]; [@b84-molcell-37-6-441]). Furthermore, obesity increases the risk of diabetes, heart disease, stroke, hypertension, and depression ([@b83-molcell-37-6-441]). In 2008, diabetes alone accounted for 1.3 million deaths ([@b84-molcell-37-6-441]). In recent years, several studies have illustrated the chronic pro-inflammatory processes involved in the onset of metabolic disorders, including obesity and diabetes ([@b6-molcell-37-6-441]).

Obesity can stem from a variety of factors, such as genetics, aging, and unhealthy lifestyle habits ([@b70-molcell-37-6-441]). Adipose tissue in obese individuals releases more free fatty acids, hormones (i.e., leptin), pro-inflammatory cytokines (i.e., TNF-α, IL-1β), signaling proteins, and transcription factors that lead to insulin resistance ([@b69-molcell-37-6-441]; [@b81-molcell-37-6-441]). Insulin resistance associated with dysfunctional insulin release from pancreatic islet β-cells impairs blood glucose tolerance, which typifies the development of T2DM ([@b32-molcell-37-6-441]).

Obesity
-------

Inflammation is associated with metabolic disorders, such as obesity. Recent studies have shown that the NLRP3 inflammasome may contribute to obesity. For example, weight loss due to calorie restriction or exercise in obese individuals with T2DM not only reduced NLRP3 expression and inflammation in adipose tissue and liver, but also improved insulin sensitivity ([@b76-molcell-37-6-441]). In addition, mice deficient in NLRP3, ASC, and caspase-1 did not exhibit obesity-induced insulin resistance, which suggests that the NLRP3 inflammasome may act as a cellular regulator of insulin sensitivity ([@b76-molcell-37-6-441]). However, since loss of NLRP3 function did not affect caspase-1 activation in the kidney of obese mice, inflammasomes may contribute to obesity *via* tissue-specific mechanisms ([@b76-molcell-37-6-441]).

Two recent reports have implicated that caspase-1 may regulate lipid metabolism, thereby controlling the induction of obesity. Both studies showed that *Casp1^−/−^* mice with lean phenotype exhibited reduced plasma triglyceride levels ([@b37-molcell-37-6-441]; [@b77-molcell-37-6-441]). While [@b77-molcell-37-6-441] illustrated a marked decrease in intestinal lipid absorption, [@b37-molcell-37-6-441] found enhanced triglyceride clearance from the circulation without alterations in lipid production or intestinal. The lipid clearance in *Casp1^−/−^* mice was also observed in *NLRP3^−/−^* mice, irrespective of IL-1β and IL-18 signaling ([@b37-molcell-37-6-441]). Therefore, the NLRP3 inflammasome appears to affect lipid metabolism in obesity independently of IL-1β and IL-18 signaling. However, negligible changes in triglyceride and cholesterol levels were observed in obese *Casp1^−/−^* or *NLRP3^−/−^* mice ([@b72-molcell-37-6-441]; [@b73-molcell-37-6-441]; [@b76-molcell-37-6-441]). Thus, the role of NLRP3 activation in lipid metabolism related to obesity remains unclear.

Release of the NLRP3 inflammasome following diet-induced obesity has been shown to induce adipocyte differentiation, which also enhanced IL-1β production and insulin resistance in adipose tissue ([@b72-molcell-37-6-441]) and increased adipocyte size ([@b73-molcell-37-6-441]). Elevated MSU levels have been linked to oxidative stress in adipocytes and obesity ([@b65-molcell-37-6-441]). Considering the recognition of MSU by the NLRP3 inflammasome, thereby inducing an inflammatory response, NLRP3 activation may contribute to insulin resistance in obesity ([@b27-molcell-37-6-441]; [@b48-molcell-37-6-441]). Furthermore, inhibited recognition of such stimuli due to NLRP3 dysfunction may prevent chronic obesity ([@b76-molcell-37-6-441]).

Type 2 diabetes mellitus (T2DM)
-------------------------------

Type 2 diabetes mellitus (T2DM) is an auto-inflammatory disease induced by metabolic stressors, such as elevated levels of glucose and free fatty acids (FFAs) ([@b8-molcell-37-6-441]). Many studies have indicated a critical role of inflammatory processes in cases related to T2DM. For example, pro-inflammatory cytokines, TNF-α, IL-1β and IFNγ, activate signaling pathways that result in pancreatic β-cell death and dysfunction ([@b11-molcell-37-6-441]; [@b14-molcell-37-6-441]; [@b54-molcell-37-6-441]). As a result, elevated IL-1β levels and limited β-cell function are two primary predictors for the development of T2DM through inhibition of insulin signaling ([@b78-molcell-37-6-441]). Additionally, recent studies have shown that inhibition of IL-1β production reduced T2DM prevalence in animal models ([@b12-molcell-37-6-441]; [@b45-molcell-37-6-441]). Furthermore, NLRP3-dependent IL-1β secretion during metabolic stress due to chronic hyperglycemia may contribute to the development of T2DM ([@b66-molcell-37-6-441]). These findings suggest that IL-1β production *via* NLRP3 inflammasome activation is involved in the pathogenesis of T2DM.

The NLRP3 inflammasome has been shown to bind to thioredoxin interacting protein (TXNIP), which facilitates ROS-mediated NLRP3 activation *via* inhibition of thioredoxin ([@b70-molcell-37-6-441]). A recent study has illustrated a potential role for TXNIP in innate immunity *via* formation of the NLRP3 inflammasome and release of IL-1β in diabetes and oxidative stress ([@b7-molcell-37-6-441]). Also, pancreatic β-cell death and insulin resistance in T2DM have been associated with IL-1β secretion mediated by the ROS-TXNIP axis, thereby enhancing NLRP3 activation ([@b86-molcell-37-6-441]). This involvement of ROSTXNIP in T2DM is consistent with the requirement for ROS in the NLRP3 inflammasome pathway ([@b78-molcell-37-6-441]). Therefore, the NLRP3 inflammasome may contribute to the pathogenesis of T2DM *via* the TXNIP protein ([@b78-molcell-37-6-441]). However, the mechanisms that induce ROS generation in response to metabolic stress, such as chronic hyperglycemia, remain incompletely understood.

Targeting specific components of the inflammasome pathway may provide a plausible approach for treatment of T2DM. For example, glibenclamide, a drug widely used to treat T2DM, has been shown to inhibit formation of the glucose-induced TXNIPNLRP3 inflammasome complex ([@b86-molcell-37-6-441]). Palmitate, a saturated fatty acid found in plasma, triggers the secretion of IL-1β and IL-18 from macrophages *via* an NLRP3-dependent pathway ([@b82-molcell-37-6-441]). In addition, islet amyloid polypeptide (IAPP), a protein that forms amyloid deposits in the pancreas during T2DM, enhanced IL-1β secretion and NLRP3 activation *in vitro* ([@b50-molcell-37-6-441]). However, this same study reported that IL-1β release in response to IAPP depended on NLRP3, but not TXNIP ([@b50-molcell-37-6-441]). Therefore, TXNIP appears to represent an agonist-dependent protein within the NLRP3 inflammasome pathway.

NLRP3 inflammasome in cognitive diseases
----------------------------------------

Although neurocognitive diseases, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and major depressive disorder (MDD), are not often characterized as typical inflammatory diseases, recent research has indicated that activation of the innate immune system may contribute to their pathogenesis ([@b18-molcell-37-6-441]). PRRs, such as the TLR4 receptor, are highly expressed on immune cells (i.e., microglia and astrocytes) that induce inflammatory processes *via* cytokine secretion ([@b64-molcell-37-6-441]). Considering that TLR4 polymorphisms have been linked to several human age-related diseases (i.e., Alzheimer's disease, atherosclerosis, and T2DM), such receptors may influence neurodegenerative diseases *via* inflammatory responses ([@b3-molcell-37-6-441]). In addition to PRRs, purinergic receptors (i.e., P2X~7~R) are expressed on microglia and astrocytes. Furthermore, upregulation of this receptor has been reported in mouse models of Alzheimer's disease ([@b56-molcell-37-6-441]). Thus, PRRs and purinergic receptors on immune cells appear not only to serve as initial sensors of microbial pathogens, but they also likely induce inflammatory pathways associated with cognitive diseases, such as Alzheimer's disease and MDD ([@b18-molcell-37-6-441]).

Alzheimer's disease
-------------------

Alzheimer's disease is characterized by progressive dementia that stems from accumulation of amyloid-beta (Aβ) plaques in the cerebrum, which leads to chronic inflammation and subsequent neuronal cell death ([@b40-molcell-37-6-441]). During the 1980s, patients suffering from Alzheimer's disease exhibited elevated levels of microglia, the primary phagocyte in the central nervous system (CNS) ([@b29-molcell-37-6-441]; [@b51-molcell-37-6-441]). Since then, amyloid plaques have been shown to activate microglia, thereby inducing the neuronal abnormalities associated with Alzheimer's disease ([@b53-molcell-37-6-441]). However, it is still debated whether Aβ accumulation is the result of chronic inflammation in amyloid-effected tissue or other disease-related processes ([@b40-molcell-37-6-441]).

Numerous studies have identified a critical role for IL-1β and the NLRP3 inflammasome in the pathogenesis of Alzheimer's disease. For example, [@b21-molcell-37-6-441] reported that Aβ phagocytosis induced IL-1β secretion *via* NLRP3-dependent activation of caspase-1, thereby suggesting involvement of the NLRP3 inflammasome in Alzheimer's disease. Exposing LPS-primed macrophages to fibrillar Aβ activated caspase-1 and triggered IL-1β release; this response was dependent on NLRP3 and involved both endosomal rupture and cathepsin B release ([@b21-molcell-37-6-441]). Furthermore, inhibition of cathepsin B has been shown to provide therapeutic benefit in a mouse model of Alzheimer's disease ([@b26-molcell-37-6-441]). Considering the role of cathepsin B in caspase-1 activation, this finding provides further evidence for the involvement of the NLRP3 inflammasome pathway in Alzheimer's disease.

A recent study reported upstream inflammatory processes in the context of Alzheimer's disease *in vivo* ([@b23-molcell-37-6-441]). *NLRP^−/−^* or *Casp1^−/−^* mice crossed into APP/PS1 transgenic mice with mutations associated with Alzheimer's disease ([@b31-molcell-37-6-441]) exhibited reduced symptoms associated with this cognitive disease, including chronic Aβ secretion, neuronal inflammation, and cognitive impairment ([@b23-molcell-37-6-441]). The same study demonstrated reduced release of caspase-1 and IL-1β in the brain and enhanced Aβ clearance, which suggests that NLRP3 functions in the pathogenesis of Alzheimer's disease ([@b23-molcell-37-6-441]). More importantly, these findings indicate that innate immune responses, specifically those related to inflammasome activation, contribute to neurocognitive disease onset and progression.

Major depressive disorder (MDD)
-------------------------------

Major depressive disorder (MDD), also known as depression, is a severe neuropsychiatric illness that involves significant changes in mood, self-esteem, circadian rhythms, eating, and cognition ([@b30-molcell-37-6-441]). While MDD affects at least 10% of the population in the United States ([@b34-molcell-37-6-441]), its biosynthetic pathway remains unresolved. Previous studies suggest that environmental stimuli can lead to inflammatory processes (i.e., cytokine secretion and NLRP3 inflammasome activation), neurological changes, and MDD onset. For example, inflammatory cytokines (i.e., IL-1β, IL-6, and TNF-α) have been shown to play an important role in major depression ([@b10-molcell-37-6-441]; [@b44-molcell-37-6-441]). Moreover, Iwata and colleagues have proposed that IL-1β secretion represents the initial step of the pro-inflammatory response to psychological stress ([@b30-molcell-37-6-441]). In agreement with this proposal, IL-1β release has been implicated to facilitate depressive behaviors (i.e., anhedonia) *via* the NF-κB pathway following both acute (i.e., foot-shock or immobilization) and chronic unpredictable stress ([@b35-molcell-37-6-441]).

Recent literature has examined a close relationship between depression and the NLRP3 inflammasome. For example, patients diagnosed with MDD exhibit increased levels of cytokines, IL-1β and IL-18, as well as the NLRP3 inflammasome in peripheral blood mononuclear cells (PBMCs) ([@b1-molcell-37-6-441]). Also, IL-1β and NLRP3 inflammasome mRNA expression levels showed a significant increase in mouse brain following LPS-induced depression, which indicates that IL-1β and NLRP3 act as inflammatory mediators for psychological stress and depression ([@b85-molcell-37-6-441]). In contrast to recent studies that suggest a critical role for mitochondrial rupture during NLRP3 activation ([@b39-molcell-37-6-441]; [@b55-molcell-37-6-441]), the inflammasome pathway in MDD patients does not depend on mitochondrial dysfunction ([@b1-molcell-37-6-441]). As a result, the mechanisms underlying the effect of psychological stress on inflammasome formation are still debated.

Of clinical relevance, several recent studies indicate that antidepressant medications regulate inflammasome activation. For example, amitriptyline, a common tricyclic antidepressant, has been shown to inhibit IL-1β and IL-18 production, as well as NLRP3 and caspase-1 gene expression in MDD patients ([@b1-molcell-37-6-441]). In addition, glyburide, an anti-diabetic drug that inhibits caspase-1 activation and IL-1β secretion, may also serve as an effective inhibitor of NLRP3 formation following stress-induced depression ([@b38-molcell-37-6-441]). Furthermore, Warner-Schmidt and colleagues found an antagonistic relationship between antidepressant drugs and anti-inflammatory agents in patients with depression ([@b80-molcell-37-6-441]). Of note, selective serotonin reuptake inhibitors (SSRIs), but not tricyclic antidepressants, increased TNF-α and IFNγ levels in the frontal cortex, which was inhibited by anti-inflammatory agents (i.e., NSAIDs) ([@b80-molcell-37-6-441]). This finding suggests that SSRIs and tricyclic antidepressants depend on different mechanisms to interact with anti-inflammatory drugs. Therefore, future clinical trials should consider the different effects of anti-inflammatory drugs on the efficacy of antidepressant agents in patients suffering from depression ([@b80-molcell-37-6-441]).

Depression-induced NLRP3 activation has been shown to correlate with many comorbid systemic illnesses (i.e., diabetes, cancer, and cardiovascular disease) ([@b30-molcell-37-6-441]; [@b52-molcell-37-6-441]). Since cytokine secretion and inflammasome formation respond to stimuli other than invasive pathogens (i.e. psychological stressors), the inflammasome may transduce such psychological stimuli into an inflammatory response. In an evolutionary sense, the inflammasome may have adapted its pathway over time to include psychological stress due to the social interaction and non-pathogenic danger signals from the environment ([@b63-molcell-37-6-441]). Considering the prevalence and potential consequences of major depressive disorder, future research should continue to focus on the role of inflammasome activation in this disease.

CONCLUSION
==========

Inflammasomes are multi-protein complexes involved in the immune system and inflammation. In this review, we have elaborated on the involvement of the NLRP3 inflammasome in various metabolic and cognitive diseases, including obesity, type 2 diabetes mellitus, Alzheimer's disease, and major depressive disorder. In addition, other neurodegenerative diseases, such as Parkinson's disease ([@b42-molcell-37-6-441]; [@b79-molcell-37-6-441]) and Huntington's disease ([@b19-molcell-37-6-441]), have been associated with the NLRP3 inflammasome. While this review focused on NLRP3, other inflammasomes, such as those belonging to the NLR family and the AIM2 inflammasome, may provide a foundation for future research. Due to potential pleiotropic effects of inflammasome formation and their associated cytokines in various disease models, further elucidation of their regulation and functional significance is warranted. Novel therapeutic strategies for modulation of inflammasome activation should continue to be developed for possible clinical application in the near future.

![The NLRP3 inflammasome regulates the caspase-1 dependent maturation and secretion of pro-inflammatory cytokines. Activation of the NLRP3 inflammasome typically requires a bimodal signaling pathway. A Toll-like receptor (TLR)-dependent priming step activates the NF-κB-dependent transcription of NLRP3 and the pro-forms of the pro-inflammatory cytokines (i.e., IL-1β and IL-18). A second signal involves the activation of the P2X~7~R receptor by stimulation with exogenous ATP, which triggers potassium ion (K^+^) efflux. Oligomerization of NLRP3 is followed by recruitment of the adaptor molecule ASC and the pro-form of caspase-1, leading to the activation (cleavage) of caspase-1. Activated caspase-1 in turn catalyzes the cleavage of IL-1β and IL-18. The NLRP3 inflammsome may be activated by agents that cause mitochondrial dysfunction, leading to the generation of mitochondrial reactive oxygen species (ROS). Furthermore, the NLRP3 inflammasome may be activated by particulates such as monosodium urate or silica, in a mechanism that may involve disruption of the lysosomes.](molcell-37-6-441f1){#f1-molcell-37-6-441}

![NLRP3 has been implicated in pro-pathogenic responses related to several human diseases, including neurocognitive disorders and metabolic disorders, although the mechanisms remain incompletely clear. Neurons and astrocytes may represent targets of NLRP3-dependent inflammatory processes, leading to the promotion of neurocognitive disorders. Adipocyte differentiation and growth have been linked to NLRP3-dependent processes in obesity. Hepatic insulin resistance and inflammation may also be mediated in part by NLRP3-dependent inflammation.](molcell-37-6-441f2){#f2-molcell-37-6-441}
